Research Alliance Corp. II
RACB
NASDAQ Capital Market10.11
USD
- -
- -
CIK
0001819724
ISIN
US7608731094
CUSIP
760873109
Return %
Stock
S&P500
1Y
4.18
18.21
3Y
-1.03
64.38
5Y
-1.03
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 3172 North Rainbow Boulevard Las Vegas NV United States of America 89108
- IPO Date
- Mar 18, 2021
- CIK
- 0001819724
- Website
- researchalliancecorpii.com
- Similar Companies
- Business
- Research Alliance Corp. II (RACB) operates as a blank check company, or special purpose acquisition company (SPAC), whose purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses; it focuses on the healthcare industry, with an emphasis on the biotechnology sector, and does not engage in any significant operations or generate revenues prior to completing such a transaction. The company targets businesses that can be funded at least one year past key value inflection points and leverages expertise from sponsor RA Capital Management, L.P. Founded on July 17, 2020, by Peter Kolchinsky (co-founder, chairman, and CEO), Matthew Hammond, and Tess Cameron, it is headquartered in Las Vegas, Nevada. In March 2021, Research Alliance Corp. II completed an initial public offering of $149.5 million, issuing 14.95 million Class A ordinary shares at $10 each, including the full exercise of the underwriter option, with Jefferies serving as lead manager; proceeds were held in trust for use in a business combination. The company maintains a forward purchase agreement allowing up to an additional $30 million from its sponsor at the closing of a potential acquisition. Geographically, operations are global, with a primary focus on U.S.-based healthcare and biotech targets. In a major development, the company announced on November 28, 2022, that it would redeem all outstanding public Class A common shares effective December 2, 2022, following stockholder approval of an amendment to extend its charter; this ceased operations except for winding up, triggered Nasdaq delisting via Form 25 and SEC deregistration via Form 15. As of late 2025, the entity remains inactive or liquidated, with no announced merger, acquisition, or further business combination activity. It reports no subsidiaries or parent company relationships beyond its sponsorship by RA Capital Management, L.P., and serves institutional and public investors seeking exposure to pre-deal SPAC structures.
Research Alliance Corp. II Will Redeem Public Shares
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Research Alliance Corp. I - RACA
Research Alliance Corp. II, Sponsored by RA Capital Management, L.P., Announces Closing of $149.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option to Purchase Additional Shares